CSS
PSTV

Cubist Systematic Strategies’s Plus Therapeutics PSTV Stock Holding History

Cubist Systematic Strategies’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$7.97K Buy
466
+57
+14% +$700 ﹤0.01% 2929
2025
Q2 		$3.56K Buy
+409
New +$5.35K ﹤0.01% 2863

Other funds holding PSTV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

Cubist Systematic Strategies's PSTV Position: Q3 2025 in Review

Cubist Systematic Strategies increased its Plus Therapeutics (PSTV) stake by 14% in Q3 2025, buying an estimated $700 and bringing the position to 466 shares worth $7.97K. The position accounts for ﹤0.01% of the portfolio, ranked #2929.

Cubist Systematic Strategies first reported a position in PSTV in Q2 2025 and has held it in 2 quarters since. 20 funds tracked by Wall St. Rank hold PSTV as of Q3 2025.

  • Cubist Systematic Strategies held 466 shares of Plus Therapeutics worth $7.97K as of Q3 2025.
  • Cubist Systematic Strategies bought 57 Plus Therapeutics shares in Q3 2025, an estimated $700.
  • Plus Therapeutics made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2929 holding.
  • Cubist Systematic Strategies first reported a position in Plus Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 20 funds tracked by Wall St. Rank held Plus Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.